These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Understanding platinum-induced ototoxicity. Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Trends Pharmacol Sci; 2013 Aug; 34(8):458-69. PubMed ID: 23769626 [Abstract] [Full Text] [Related]
23. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S. J Clin Oncol; 2014 Feb 20; 32(6):527-34. PubMed ID: 24419114 [Abstract] [Full Text] [Related]
24. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Cancer Epidemiol; 2022 Aug 20; 79():102203. PubMed ID: 35724557 [Abstract] [Full Text] [Related]
25. Practical grading system for evaluating cisplatin ototoxicity in children. Chang KW, Chinosornvatana N. J Clin Oncol; 2010 Apr 01; 28(10):1788-95. PubMed ID: 20194861 [Abstract] [Full Text] [Related]
26. The incidence of hearing impairment after successful treatment of neuroblastoma. Simon T, Hero B, Dupuis W, Selle B, Berthold F. Klin Padiatr; 2002 Apr 01; 214(4):149-52. PubMed ID: 12165893 [Abstract] [Full Text] [Related]
28. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink MM, Carleton B. PLoS One; 2019 Apr 01; 14(2):e0210646. PubMed ID: 30763334 [Abstract] [Full Text] [Related]
29. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG. Pediatr Blood Cancer; 2014 Apr 01; 61(4):601-5. PubMed ID: 24504791 [Abstract] [Full Text] [Related]
32. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Pediatr Blood Cancer; 2012 Jul 15; 59(1):144-8. PubMed ID: 22431292 [Abstract] [Full Text] [Related]
33. Long term hearing degeneration after platinum-based chemotherapy in childhood. Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Grenner J, Magnusson M, Moëll C. Int J Audiol; 2010 Oct 15; 49(10):765-71. PubMed ID: 20874050 [Abstract] [Full Text] [Related]
34. Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association. Sherief LM, Rifky E, Attia M, Ahmed R, Kamal NM, Oshi MAM, Hanna D. Medicine (Baltimore); 2022 Nov 11; 101(45):e31627. PubMed ID: 36397425 [Abstract] [Full Text] [Related]
35. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U, Pakakasama S, Hongeng S. J Pediatr Hematol Oncol; 2013 May 11; 35(4):e138-43. PubMed ID: 23274376 [Abstract] [Full Text] [Related]
37. Ototoxicity in children treated for osteosarcoma. Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. Pediatr Blood Cancer; 2009 Mar 11; 52(3):387-91. PubMed ID: 19061216 [Abstract] [Full Text] [Related]